- Previous Close
1.6400 - Open
1.6360 - Bid 1.7100 x --
- Ask 1.7120 x --
- Day's Range
1.6300 - 1.7160 - 52 Week Range
0.6330 - 4.8850 - Volume
295,188 - Avg. Volume
454,671 - Market Cap (intraday)
274.576M - Beta (5Y Monthly) 1.93
- PE Ratio (TTM)
-- - EPS (TTM)
-0.2700 - Earnings Date May 21, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
0.77
Isofol Medical AB (publ), a clinical stage biotech company, develops, commercializes, and sells oncology drugs in Sweden and internationally. The company develops arfolitixorin, which is in phase 3 clinical trial for the treatment of advanced colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden.
isofolmedical.comRecent News: ISOFOL.ST
View More
Performance Overview: ISOFOL.ST
Trailing total returns as of 3/20/2025, which may include dividends or other distributions. Benchmark is OMX Stockholm 30 Index (^OMX) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ISOFOL.ST
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ISOFOL.ST
View MoreValuation Measures
Market Cap
264.89M
Enterprise Value
120.66M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
3.40
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-24.69%
Return on Equity (ttm)
-43.62%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-43.49M
Diluted EPS (ttm)
-0.2700
Balance Sheet and Cash Flow
Total Cash (mrq)
96.16M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-27.75M
Research Analysis: ISOFOL.ST
View MoreCompany Insights: ISOFOL.ST
ISOFOL.ST does not have Company Insights